Skip to contents

Seo Young Kim, MD, ScD, MSCE
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Phar Epid & Phar Econ
75 Francis Street
Boston, MA 02115

Research Location: One Brigham Circle

Fax: 617-232-8602
Email: skim62@partners.org

Edit Profile


Research Narrative:

Seoyoung C. Kim, MD, ScD, MSCE, is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics and coappointed in the Division of Rheumatology, Immunology and Allergy at the Brigham and Women’s Hospital. Her research focuses on comparative safety and effectiveness of medications for the rheumatic diseases as well as health services/outcome research in Rheumatology.

Dr. Kim has received several NIH research grants including a current R01 study to determine the safey of long-term opioid use in patients undergoing total joint replacement for hip or knee arthritis.  

 


Education:
Harvard School of Public Health, 2014, ScD
University of Pennsylvania , 2009, MSCE
Hanyang University, College of Medicine, 2000, MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Kang EH, Jin Y, Tong AY, Desai RJ, Kim SC. Risk of serious infection among initiators of TNF inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study. Arthritis Care Res (Hoboken). 2019 Aug 03.

2. Kang EH, Kim SC. Cardiovascular Safety of Urate Lowering Therapies. Curr Rheumatol Rep. 2019 Jul 24; 21(9):48.

3. Desai RJ, Kim SC, Curtis JR, Bosco JLF, Eichelberger B, Barr CE, Lockhart CM, Bradbury BD, Clewell J, Cohen HP, Gagne JJ. Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. Pharmacoepidemiol Drug Saf. 2019 Jul 12.

4. Yu Z, Kim SC, Vanni K, Huang J, Desai R, Murphy SN, Solomon DH, Liao KP. Correction to: Association between inflammation and systolic blood pressure in RA compared to patients without RA. Arthritis Res Ther. 2019 Jul 08; 21(1):170.

5. Kim SC, Jin Y, Lee YC, Lii J, Franklin PD, Solomon DH, Franklin JM, Katz JN, Desai RJ. Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. JAMA Netw Open. 2019 Jul 03; 2(7):e198061.

6. Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fracture Risk After Initiation of Use of Canagliflozin. Ann Intern Med. 2019 Jul 02; 171(1):80.

7. Jin Y, Solomon DH, Franklin PD, Lee YC, Lii J, Katz JN, Kim SC. Patterns of prescription opioid use before total hip and knee replacement among US Medicare enrollees. Osteoarthritis Cartilage. 2019 Jun 26.

8. Chen SK, Feldman CH, Brill G, Lee YC, Desai RJ, Kim SC. Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. BMJ Open. 2019 Jun 19; 9(6):e027495.

9. Tedeschi SK, Kim SC, Guan H, Grossman JM, Costenbader KH. Comparative Fracture Risks Among United States Medicaid Enrollees With and Those Without Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Jul; 71(7):1141-1146.

10. Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. JAMA Dermatol. 2019 Jun 01; 155(6):700-707.